BioSpace News Archive

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data from the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer, which further validates the potential of the drug. The presentation will be held a

61.9% of patients with HER2-mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the US for ENHERTU in this setting

Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-positive advanced breast cancer. This is a FIH clinical trial of ALT-P7, a HER2-targeting ADC, and is a single-group, dose-escalation study designed to determine the maximum tolerated dose (MTD) and evaluate the safety of

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present a corporate overview at the Jefferies 2020 Virtual Healthcare Conference, being held June 2-4, 2020

SEngine Precision Medicine , a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor-based organoids, today presented data on the predictive value of the PARIS® Test in its poster, “Predictive value of a CLIA-approved organoid based drug sensitivity test” (poster board #360), during the 2020 ASCO Virtual Meeting being held May 29 – 31, 2020. The PARIS® Test is CLIA certified

Persistence Market Research (PMR) delivers key insights on the global hepatitis C treatment market in its latest report titled “Hepatitis C Treatment Market: Global Industry Analysis and Forecast, 2016–2024”.

ECG monitoring devices are experiencing a paradigm technological shift from resting ECG systems to portable Holter monitoring systems. According to a new report by Persistence Market Research (PMR), titled, “Holter Monitoring Systems Market: Global Industry Analysis and Forecast, 2016-2024”, this is attributed to advantages such as patient mobility, low prices, and longer period of patient monitoring.

Persistence Market Research’s recent report on “Global Market Study on Kidney Dialysis Equipment: Latin America Expected to Emerge the Third Attractive Regional Market ” forecasts the market revenues to reach US$ 25.128 Bn by 2024 end. The US$ 15 Bn kidney dialysis market is projected to grow at a CAGR of 6.5% through 2024.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Health risks of unattended wounds or undue exposure to infected tissues are becoming an alarming concern in the healthcare industry of North America. Ineffectiveness of conventional wound care products continues to impede the surgical improvement of patients being treated with infected diseases.